This is based on in vitro assay of the acquired infection‐associated viral antigen‐specific IgG Ab titers against the virus that if used for treatment early in the illness could help block the COVID‐19 viral spike protein crucial pathogenetic interaction with the specific viral receptor ACE2 on bronchial epithelial cells and/or bind virus to clear the agent via complement and IgG Fc‐dependent actions. The gene discussed is ACE2; the disease is infection.